2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-101325
    (S,S)-BRL-37344 sodium 127299-93-8 ≥99.0%
    (S,S)-BRL-37344 sodium is an isomer of BRL-37344 (HY-101325B). BRL-37344 is a β-adrenoceptor agonist with EC50 values of 5.3, 18 and 570 nM for β3, β2 and β1. BRL-37344 induces concentration-dependent increases in atria1 rate, relaxation of guinea pig trachea and lipolysis of brown adipocytes.
    (S,S)-BRL-37344 sodium
  • HY-103189
    VUF-5574 280570-45-8 99.0%
    VUF-5574 is a selective antagonist of adenosine A3 receptor with a Ki of 4.03 nM for the recombinant human receptor.
    VUF-5574
  • HY-107580
    GPR109 receptor agonist-1 306935-41-1 99.94%
    GPR109 receptor agonist-1 is a highly selective agonist of the human orphan G protein-coupled receptor GPR109b, and does not activate the mouse homologous receptor PUMA-G. GPR109 receptor agonist-1 functionally modulates the human GPR109b receptor via the cAMP signaling pathway, with an EC50 of 400 nM. GPR109 receptor agonist-1 inhibits isoproterenol (HY-B0468)-stimulated lipolysis in human subcutaneous adipocytes, with efficacy comparable to that of Niacin (HY-B0143), and does not act on β-adrenergic receptors. GPR109 receptor agonist-1 can be used in studies related to dyslipidemia and atherosclerosis.
    GPR109 receptor agonist-1
  • HY-108571
    CP-775146 702680-17-9 98.70%
    CP-775146 is a selective PPARα agonist (Ki of 24.5 nM) that binds strongly to the PPARα ligand. CP-775146 has no observable affinity for PPARβ and PPARγ.CP-775146 shows hypolipidemic activity. CP-775146 efficiently alleviates obesity-induced liver damage, prevents lipid accumulation by activating the liver fatty acid β-oxidation pathway.
    CP-775146
  • HY-109897
    CV-6209 100488-87-7
    CV-6209 is a potent antagonist of platelet activating factor (PAF). CV-6209 inhibits the PAF-induced aggregation of rabbit and human platelets, with IC50s of 75 nM and 170 nM, respectively. CV-6209 can inhibit PAF-induced hypotension in rats.
    CV-6209
  • HY-112275
    TNF-α-IN-1 444287-49-4 99.20%
    TNF-α-IN-1 (Compound I-7) is a TNF-α inhibitor. TNF-α-IN-1 can be studied in research for cancers, heart disease, autoimmune disease and infections.
    TNF-α-IN-1
  • HY-114086
    ML359 1069858-99-6 99.45%
    ML359 is a potent, selctive and reversible inhibitor of protein disulfide isomerase (PDI), with an IC50 of 250 nM. ML359 can prevent thrombus formation in vivo.
    ML359
  • HY-116513
    Adrenochrome 54-06-8 99.22%
    Adrenochrome (Adraxone) is an oxidation product of Epinephrine. Adrenochrome is a potent coronary constricting agent in the rat heart. Adrenochrome can be used for neurological disorder research.
    Adrenochrome
  • HY-118060
    Dipeptide 2 24587-37-9 98.12%
    Dipeptide 2 (N-Valyltryptophan) is an orally active, competitive angiotensin-converting enzyme (ACE) inhibitory peptide with an IC50 of 10.50 μM. Dipeptide 2 reduces intracellular Calcium ions. Dipeptide 2 significantly increases the content of NO, inhibits the production of ET-1, and induces the phosphorylation of eNOS. Dipeptide 2 decreases the systolic and diastolic blood pressure of spontaneously hypertensive rats.
    Dipeptide 2
  • HY-119909
    GNX-865 1223568-82-8 98.09%
    GNX-865 is a mitochondrial permeability transition pore (mPTP) inhibitor that protects against ischemia-reperfusion injury in vivo.
    GNX-865
  • HY-125639
    (rac)-AR-13503 1254032-16-0 99.08%
    (rac)-AR-13503 ((rac)-AR-13324 M1 metabolite) is the isoform of AR-13503 (HY-12798C). AR-13503 a ROCK/PKC inhibitor, inhibiting angiogenesis and enhancing retinal pigment epithelium (RPE) permeability. AR-13503 also inhibits the formation of aberrant neovascularization (NV) in oxygen-induced retinopathy (OIR) model in mice.
    (rac)-AR-13503
  • HY-125643
    Pitavastatin lactone 141750-63-2 98.74%
    Pitavastatin lactone is a major metabolite of Pitavastatin (HY-B0144A) in humans. Pitavastatin is a potent competitive inhibitor of HMG-CoA reductase.
    Pitavastatin lactone
  • HY-128932
    Cefminox sodium 75498-96-3 99.83%
    Cefminox sodium (MT-141) is a semisynthetic cephamycin, which exhibits antibacterial activity. Cefminox sodium is a broad-spectrum, bactericidal cephalosporin antibiotic. Cefminox sodium also acts as a dual agonist of prostacyclin receptor (IP) and PPARγ. Cefminox sodium upregulates cAMP production and PTEN expression and inhibits Akt/mTOR signaling. Cefminox sodium also prevents pulmonary arterial hypertension in rat model.
    Cefminox sodium
  • HY-130345
    PAF (C18) 74389-69-8 99.89%
    C18-PAF, octadecane PAF, is the ligand of platelet-activating factor and PAF G protein-coupled receptor (PAFR). C18-PAF has renovasodilator properties and antihypertensive lipid properties. C18-PAF increases renal blood flow and causes dose-dependent systemic hypotension.
    PAF (C18)
  • HY-135326
    4-Propionamidophenol 1693-37-4 99.89%
    4-Propionamidophenol is an important intermediate of alkanolamine derivatives with β-adrenergic blocking activity. 4-Propionamidophenol can be used in the study of diseases such as heart disease and hypertension.
    4-Propionamidophenol
  • HY-136661
    (-)-N6-Phenylisopropyl adenosine 38594-96-6 99.45%
    (-)-N6-phenylisopropyl adenosine (L-Phenylisopropyladenosine) is a selective A1 adenosine receptor agonist. (-)-N6-phenylisopropyl adenosine inhibits K+-induced Ca2+ uptake with an IC50 value of 0.5 µM. (-)-N6-phenylisopropyl adenosine protects against ischemia-induced ventricular arrhythmias and atrial fibrillation, and exacerbates ethanol withdrawal symptoms. (-)-N6-phenylisopropyl adenosine also has analgesic effects.
    (-)-N6-Phenylisopropyl adenosine
  • HY-153977
    GLX481304 701224-63-7 98.94%
    GLX481304 is a specific inhibitor of Nox-2 and -4, with IC50s of 1.25 μM. GLX481304 suppresses ROS production in isolated mouse cardiomyocytes and improves cardiomyocyte contractility. GLX481304 can be used for research of ischemic injury to the heart.
    GLX481304
  • HY-15407A
    Sacubitril hemicalcium salt 1369773-39-6 ≥98.0%
    Sacubitril hemicalcium salt (AHU-377 hemicalcium salt) is a potent NEP inhibitor with an IC50 of 5 nM. Sacubitril hemicalcium salt is a component of the heart failure medicine LCZ696.
    Sacubitril hemicalcium salt
  • HY-15833S
    Chlorthalidone-d4 1794941-44-8 98.49%
    Chlorthalidone-d4 is the deuterium labeled Chlorthalidone. Chlorthalidone is a thiazide-like diuretic used to treat hypertension.
    Chlorthalidone-d4
  • HY-162322
    VU0542270 1396814-79-1 98.48%
    VU0542270 is a selective vascular Kir6.1/SUR2B KATP channel inhibitor with an IC50 value of 100 nM. VU0542270 has an IC50 > 30 μM for the other nine members of the Kir channel family. VU0542270 can be used in the study of cardiovascular disease.
    VU0542270
Cat. No. Product Name / Synonyms Application Reactivity